BoomRay Pharmaceutical Co., Ltd. is a clinical-stage biotech focusing on delivering innovative radioactive targeted drugs (RDC) for precise tumor diagnosis and treatment. Currently, BoomRay has multiple clinical-stage RTD products. The company has a management team led by overseas high-profile talents with rich backgrounds in the nuclear medicine industry and experience in drug design and translation. BoomRay is committed to building itself into a first-class nuclear medicine company with original innovation and highly efficient industrial translation capabilities.